Generation of a chemical genetic model for JAK3
Authors:
Open Access
- 12 May 2021
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-13
Abstract
Janus Kinases (JAKs) have emerged as an important drug target for the treatment of a number of immune disorders due to the central role that they play in cytokine signalling. 4 isoforms of JAKs exist in mammalian cells and the ideal isoform profile of a JAK inhibitor has been the subject of much debate. JAK3 has been proposed as an ideal target due to its expression being largely restricted to the immune system and its requirement for signalling by cytokine receptors using the common γ-chain. Unlike other JAKs, JAK3 possesses a cysteine in its ATP binding pocket and this has allowed the design of isoform selective covalent JAK3 inhibitors targeting this residue. We report here that mutating this cysteine to serine does not prevent JAK3 catalytic activity but does greatly increase the IC50 for covalent JAK3 inhibitors. Mice with a Cys905Ser knockin mutation in the endogenous JAK3 gene are viable and show no apparent welfare issues. Cells from these mice show normal STAT phosphorylation in response to JAK3 dependent cytokines but are resistant to the effects of covalent JAK3 inhibitors. These mice therefore provide a chemical-genetic model to study JAK3 function.Keywords
Funding Information
- Medical Research Council (MR/M025233/1, MR/M025233/1)
This publication has 51 references indexed in Scilit:
- Inhibition of JAKs in Macrophages Increases Lipopolysaccharide-Induced Cytokine Production by Blocking IL-10–Mediated FeedbackThe Journal of Immunology, 2012
- Inborn Errors of Human JAKs and STATsImmunity, 2012
- Identification of a Potent Janus Kinase 3 Inhibitor with High Selectivity within the Janus Kinase FamilyJournal of Medicinal Chemistry, 2010
- Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasmsBlood, 2010
- A Chemical Genetic Approach Reveals That p38α MAPK Activation by Diphosphorylation Aggravates Myocardial Infarction and Is Prevented by the Direct Binding of SB203580Journal of Biological Chemistry, 2010
- The selectivity of protein kinase inhibitors: a further updateBiochemical Journal, 2007
- Role of JAK2 in the pathogenesis and therapy of myeloproliferative disordersNature Reviews Cancer, 2007
- A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia veraNature, 2005
- Mutation of Jak3 in a Patient with SCID: Essential Role of Jak3 in Lymphoid DevelopmentScience, 1995
- Defects in B Lymphocyte Maturation and T Lymphocyte Activation in Mice Lacking Jak3Science, 1995